Table 3.
Treatment Factors
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection
| Clinically detected (n = 22) | Screen-detected (n = 92) | P-value | Interval cancers (n = 11) | Screen-detected (n = 64) | P-value | |
|---|---|---|---|---|---|---|
| All Women | Regular Screeners | |||||
| Breast surgery | 0.11 | 0.14 | ||||
| Unilateral mastectomy | 0 (0%) | 1 (1%) | 0 (0%) | 1 (2%) | ||
| Bilateral mastectomy | 20 (91%) | 74 (80%) | 9 (82%) | 48 (75%) | ||
| Lumpectomy | 1 (5%) | 17 (19%) | 1 (9%) | 15 (23%) | ||
| None | 1 (5%) | 0 (0%) | 1 (9%) | 0 (0%) | ||
| Axillary surgery* | 0.01 | 0.03 | ||||
| SLNB only | 14 (64%) | 65 (90%) | 7 (64%) | 47 (92%) | ||
| SLNB+ALND or ALND | 8 (36%) | 7 (10%) | 4 (36%) | 4 (8%) | ||
| Chemotherapy* | < .01 | < .01 | ||||
| Adjuvant | 14 (64%) | 37 (51%) | 7 (64%) | 31 (61%) | ||
| Neoadjuvant | 7 (32%) | 3 (4%) | 4 (36%) | 1 (2%) | ||
| None | 1 (5%) | 32 (44%) | 0 (0%) | 19 (37%) | ||
| Endocrine therapy** | 11 (92%) | 32 (87%) | 1 | 5 (100%) | 24 (86%) | 1 |
| Postmastectomy radiation therapy† | 6 (30%) | 7 (12%) | 0.08 | 1 (11%) | 5 (12%) | 1 |
*
Among invasive cancers only
**
Among invasive estrogen receptor positive cancers only
†
Among patients undergoing mastectomy for invasive cancer